Cronos Group Inc (CRON)

$2.5

+0.02

(+0.81%)▲

Market is closed - opens 7 PM, 26 Apr 2024

Insights on Cronos Group Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 33.91M → 24.57M (in $), with an average decrease of 27.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -1.64M → -46.04M (in $), with an average decrease of 2700.6% per quarter

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 39.5% return, outperforming this stock by 109.6%

Performance

  • $2.46
    $2.53
    $2.50
    downward going graph

    1.6%

    Downside

    Day's Volatility :2.77%

    Upside

    1.19%

    downward going graph
  • $1.64
    $2.99
    $2.50
    downward going graph

    34.4%

    Downside

    52 Weeks Volatility :45.15%

    Upside

    16.39%

    downward going graph

Returns

PeriodCronos Group IncSector (Health Care)Index (Russel 2000)
3 Months
27.55%
0.5%
0.0%
6 Months
44.51%
11.7%
0.0%
1 Year
44.51%
6.2%
2.2%
3 Years
-70.1%
13.5%
-23.0%

Highlights

Market Capitalization
946.2M
Book Value
$2.88
Earnings Per Share (EPS)
-0.18
Wall Street Target Price
2.61
Profit Margin
-84.78%
Operating Margin TTM
-75.97%
Return On Assets TTM
-4.25%
Return On Equity TTM
-6.3%
Revenue TTM
87.2M
Revenue Per Share TTM
0.23
Quarterly Revenue Growth YOY
8.5%
Gross Profit TTM
12.0M
EBITDA
-72.5M
Diluted Eps TTM
-0.18
Quarterly Earnings Growth YOY
0.14
EPS Estimate Current Year
-0.08
EPS Estimate Next Year
-0.08
EPS Estimate Current Quarter
-0.01
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    57%Buy
    35%Hold
    7%Sell
Based on 14 Wall street analysts offering stock ratings for Cronos Group Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
5
6
6
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 4.4%

Current $2.50
Target $2.61

Company Financials

FY18Y/Y Change
Revenue
11.5M
↑ 255.17%
Net Income
-13.9M
↓ 803.1%
Net Profit Margin
-120.8%
↓ 181.82%
FY19Y/Y Change
Revenue
23.8M
↑ 106.0%
Net Income
2.5B
↓ 17729.39%
Net Profit Margin
10.3K%
↑ 10459.23%
FY20Y/Y Change
Revenue
46.7M
↑ 96.71%
Net Income
-74.6M
↓ 103.04%
Net Profit Margin
-159.72%
↓ 10498.15%
FY21Y/Y Change
Revenue
74.4M
↑ 59.32%
Net Income
-396.7M
↑ 431.63%
Net Profit Margin
-532.95%
↓ 373.23%
FY22Y/Y Change
Revenue
91.9M
↑ 23.47%
Net Income
-168.7M
↓ 57.47%
Net Profit Margin
-183.6%
↑ 349.35%
FY23Y/Y Change
Revenue
88.8M
↓ 3.33%
Net Income
-75.2M
↓ 55.43%
Net Profit Margin
-84.64%
↑ 98.96%
Q3 FY22Q/Q Change
Revenue
20.9M
↓ 9.27%
Net Income
-36.9M
↑ 81.36%
Net Profit Margin
-176.29%
↓ 88.1%
Q4 FY22Q/Q Change
Revenue
22.9M
↑ 9.39%
Net Income
-78.9M
↑ 113.79%
Net Profit Margin
-344.55%
↓ 168.26%
Q1 FY23Q/Q Change
Revenue
20.1M
↓ 11.98%
Net Income
-19.3M
↓ 75.58%
Net Profit Margin
-95.6%
↑ 248.95%
Q2 FY23Q/Q Change
Revenue
19.0M
↓ 5.57%
Net Income
-8.4M
↓ 56.59%
Net Profit Margin
-43.95%
↑ 51.65%
Q3 FY23Q/Q Change
Revenue
33.9M
↑ 78.29%
Net Income
-1.6M
↓ 80.33%
Net Profit Margin
-4.85%
↑ 39.1%
Q4 FY23Q/Q Change
Revenue
24.6M
↓ 27.53%
Net Income
-46.0M
↑ 2700.63%
Net Profit Margin
-187.35%
↓ 182.5%
FY18Y/Y Change
Total Assets
191.7M
↑ 138.62%
Total Liabilities
36.3M
↑ 211.59%
FY19Y/Y Change
Total Assets
2.1B
↑ 990.4%
Total Liabilities
341.4M
↑ 839.82%
FY20Y/Y Change
Total Assets
1.9B
↓ 7.88%
Total Liabilities
217.5M
↓ 36.29%
FY21Y/Y Change
Total Assets
1.4B
↓ 27.42%
Total Liabilities
63.5M
↓ 70.82%
FY22Y/Y Change
Total Assets
1.2B
↓ 13.22%
Total Liabilities
72.0M
↑ 13.52%
FY23Y/Y Change
Total Assets
1.1B
↓ 6.49%
Total Liabilities
43.7M
↓ 39.29%
Q3 FY22Q/Q Change
Total Assets
1.2B
↓ 7.11%
Total Liabilities
46.2M
↓ 2.17%
Q4 FY22Q/Q Change
Total Assets
1.2B
↓ 1.98%
Total Liabilities
72.0M
↑ 55.85%
Q1 FY23Q/Q Change
Total Assets
1.2B
↓ 4.41%
Total Liabilities
33.2M
↓ 53.95%
Q2 FY23Q/Q Change
Total Assets
1.2B
↑ 0.76%
Total Liabilities
31.7M
↓ 4.52%
Q3 FY23Q/Q Change
Total Assets
1.2B
↓ 1.56%
Total Liabilities
33.3M
↑ 5.28%
Q4 FY23Q/Q Change
Total Assets
1.1B
↓ 1.38%
Total Liabilities
43.7M
↑ 31.15%
FY18Y/Y Change
Operating Cash Flow
-7.2M
↑ 62.07%
Investing Cash Flow
-93.9M
↑ 214.11%
Financing Cash Flow
113.5M
↑ 185.18%
FY19Y/Y Change
Operating Cash Flow
-130.0M
↑ 1718.19%
Investing Cash Flow
-603.5M
↑ 542.69%
Financing Cash Flow
1.9B
↑ 1535.55%
FY20Y/Y Change
Operating Cash Flow
-142.5M
↑ 9.58%
Investing Cash Flow
20.2M
↓ 103.34%
Financing Cash Flow
-5.5M
↓ 100.29%
FY21Y/Y Change
Operating Cash Flow
-153.6M
↑ 7.83%
Investing Cash Flow
-28.9M
↓ 243.41%
Financing Cash Flow
-13.4M
↑ 145.97%
FY22Y/Y Change
Operating Cash Flow
-88.9M
↓ 42.1%
Investing Cash Flow
-1.8M
↓ 93.63%
Financing Cash Flow
-2.9M
↓ 78.45%
Q3 FY22Q/Q Change
Operating Cash Flow
-13.4M
↓ 22.54%
Investing Cash Flow
-120.0M
↑ 196.82%
Financing Cash Flow
-243.0K
↓ 84.52%
Q4 FY22Q/Q Change
Operating Cash Flow
-24.4M
↑ 82.08%
Investing Cash Flow
158.5M
↓ 232.07%
Financing Cash Flow
-620.0K
↑ 155.14%
Q1 FY23Q/Q Change
Operating Cash Flow
-47.7M
↑ 95.69%
Investing Cash Flow
-303.8M
↓ 291.73%
Financing Cash Flow
-743.0K
↑ 19.84%
Q2 FY23Q/Q Change
Operating Cash Flow
-11.8M
↓ 75.31%
Investing Cash Flow
4.8M
↓ 101.6%
Financing Cash Flow
-39.0K
↓ 94.75%

Technicals Summary

Sell

Neutral

Buy

Cronos Group Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cronos Group Inc
Cronos Group Inc
-5.3%
44.51%
44.51%
-70.1%
-85.43%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-2.41%
27.65%
34.11%
39.49%
77.94%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.12%
5.13%
-5.51%
13.36%
13.36%
Zoetis Inc.
Zoetis Inc.
-7.43%
-2.98%
-11.32%
-9.68%
48.39%
Viatris Inc.
Viatris Inc.
-1.12%
27.59%
26.04%
-15.35%
-29.8%
Catalent, Inc.
Catalent, Inc.
-0.82%
42.09%
27.6%
-51.77%
23.97%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cronos Group Inc
Cronos Group Inc
NA
NA
NA
-0.08
-0.06
-0.04
NA
2.88
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
56.26
56.26
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.82
29.82
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
29.5
29.5
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
231.0
231.0
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cronos Group Inc
Cronos Group Inc
Buy
$946.2M
-85.43%
NA
-84.78%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.1B
77.94%
56.26
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.1B
13.36%
29.82
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$68.3B
48.39%
29.5
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.7B
-29.8%
231.0
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
23.97%
211.02
-31.77%

Institutional Holdings

  • Chescapmanager LLC

    2.18%

  • Vanguard Group Inc

    1.86%

  • Dimensional Fund Advisors, Inc.

    0.53%

  • Susquehanna International Group, LLP

    0.36%

  • Millennium Management LLC

    0.33%

  • Group One Trading, LP

    0.28%

Corporate Announcements

  • Cronos Group Inc Earnings

    Cronos Group Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

cronos group is a globally diversified and vertically integrated cannabis company with a presence across four continents. the company operates two wholly-owned canadian licensed producers regulated under health canada’s access to cannabis for medical purposes regulations: peace naturals project inc. (ontario), which was the first non-incumbent medical cannabis license granted by health canada, and original bc ltd. (british columbia), which is based in the okanagan valley. the company has multiple international production and distribution platforms: cronos israel and cronos australia. through an exclusive distribution agreement, cronos also has access to over 12,000 pharmacies in germany as the company focuses on building an international iconic brand portfolio and developing disruptive intellectual property.

Organization
Cronos Group Inc
Employees
356
CEO
Mr. Michael Ryan Gorenstein J.D.
Industry
Health Technology

Discover More

FAQs